Alba Martin Centellas

Dr. Alba Martin Centellas

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SLSara Lozano-Jimenez
Sara Lozano-Jimenez
PMPaula Vela Martín
Paula Vela Martín
ACAlba Martin Centellas
Alba Martin Centellas
DCDaniel de Castro
Daniel de Castro
CMCristina Mitroi
Cristina Mitroi
MRMercedes Rivas-Lasarte
Mercedes Rivas-Lasarte
Background/Objectives: Congestion is a hallmark of heart failure (HF) and a major determinant of outcomes. Non-invasive tools enable detection of subclinical congestion, but their correlation and prognostic relevance remain incompletely defined. The present study aimed to assess the prevalence, evolution, interrelationships, and prognostic impact of clinical and subclinical congestion markers in patients hospitalized for HF. Methods: This single-centre, prospective cohort study included adults admitted with HF who underwent serial evaluations at admission, 72 h, pre-discharge, early outpatient follow-up and at 6 months. Clinical congestion was assessed using a standardized physical examination score. Subclinical congestion was evaluated using lung ultrasound (LUS), Venous Excess Ultrasound Score (VExUS), and Remote Dielectric Sensing (ReDS). Patients were classified according to the presence of clinical and/or subclinical congestion at discharge. The primary endpoint was a composite of all-cause mortality, HF readmission, or unscheduled visits requiring intravenous diuretics within six months. Results: Ninety-four patients (mean age 74 ± 11 years, 68% male) were included. While clinical congestion improved significantly during hospitalization, approximately 30% of patients remained clinically congested at discharge. Among clinically euvolemic patients, only 47% showed no evidence of subclinical congestion. Correlations between congestion markers were weak to moderate, suggesting complementary pathophysiological information. At discharge, pulmonary B-lines were the strongest predictor of the composite endpoint (hazard ratio [HR] 3.50, 95% CI 1.41–8.72), followed by clinical congestion (HR 2.67, 95% CI 1.13–6.30). Patients with clinical and subclinical congestion exhibited lower event-free survival. Conclusions: Subclinical congestion is common despite apparent clinical euvolemia and is associated with worse outcomes. Integrating clinical assessment with non-invasive congestion markers may improve post-discharge risk stratification in HF.

23 October 2025 in Clinical Transplantation
Verified
Journal Article
Open access
JGJoan Guzman‐Bofarull
Joan Guzman‐Bofarull
ACAlba Martin Centellas
Alba Martin Centellas
DMDavid Couto Mallon
David Couto Mallon
RBRoger Borràs
Roger Borràs
ALAndrea Arenas Loriente
Andrea Arenas Loriente
MFMarta Farrero-Torres
Marta Farrero-Torres
Introduction: Levosimendan, a calcium‐sensitizing inotropic agent, is used in patients with advanced heart failure (HF) awaiting heart transplantation (HT). Its prolonged effects, due to an active metabolite, may influence post‐transplant vasodilation, particularly when administered shortly before HT. However, its impact on post‐HT complications such as vasoplegia and primary graft dysfunction (PGD) remains unclear. This study aimed to evaluate whether preoperative levosimendan affects these outcomes. Methods: This retrospective, multicenter observational study included adult HT recipients from 2010 to 2022 across three Spanish centers. Patients were grouped based on whether they received levosimendan within 1 month prior to HT. Main outcomes were post‐HT vasoplegia (defined as cardiac index ≥2.5 L/min/m 2 , systemic vascular resistance 20 or norepinephrine administration >0.1 µg/kg/min at 24 h post‐HT) and severe PGD, as defined by the 2014 ISHLT criteria. Secondary outcomes included all‐cause mortality. Subgroup analyses were performed for patients receiving levosimendan within 1 week of HT and by sex. Statistical analyses included propensity score (PS) matching, Kaplan–Meier curves, and multivariate Cox regression models. Results: Among 598 HT recipients, 94 (15.7%) received levosimendan preoperatively. After PS adjustment, no significant differences were found in the incidence of vasoplegia (40.0% vs. 39.2%, OR 0.99, p = 0.98) or severe PGD (10.6% vs. 10.3%, OR 1.25, p = 0.63) between groups. Post‐HT mortality was also not different (HR 0.78, p = 0.37). Vasoplegia did not affect mortality, while severe PGD was linked to higher mortality. Subgroup and sex‐based analyses revealed no significant outcome differences. Conclusions: Pre‐HT levosimendan use was not associated with increased early post‐transplant complications and appears to be a safe strategy. Summary: This study evaluated whether giving levosimendan before HT affects early post‐transplant complications. Among 598 patients, 94 received levosimendan within a month before surgery. Results showed no significant differences in rates of vasoplegia, severe primary graft dysfunction, or mortality. Levosimendan use appears safe in the immediate pre‐transplant setting.

2 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SLSara Lozano-Jimenez
Sara Lozano-Jimenez
PMPaula Vela Martín
Paula Vela Martín
ACAlba Martin Centellas
Alba Martin Centellas
DCDaniel de Castro
Daniel de Castro
CMCristina Mitroi
Cristina Mitroi
MRMercedes Rivas-Lasarte
Mercedes Rivas-Lasarte
Background/Objectives: Congestion is a hallmark of heart failure (HF) and a major determinant of outcomes. Non-invasive tools enable detection of subclinical congestion, but their correlation and prognostic relevance remain incompletely defined. We aimed to assess the prevalence, evolution, interrelationship, and prognostic impact of clinical and subclinical congestion markers in patients hospitalized for HF. Methods: This single-centre, prospective cohort study included adults admitted with HF who underwent serial evaluations at admission, 72 hours, pre-discharge, early outpatient follow-up and at 6-month. Clinical congestion was assessed using a standardized physical examination score. Subclinical congestion was evaluated using lung ultrasound (LUS), Venous Excess Ultrasound Score (VExUS), and Remote Dielectric Sensing (ReDS). Patients were classified according to the presence of clinical and/or subclinical congestion at discharge. The primary endpoint was a composite of all-cause mortality, HF readmission, or unscheduled visits requiring intravenous diuretics within six months of follow-up. Results: Ninety-four patients (mean age 74±11 years, 68% male) were included. While clinical congestion improved significantly during hospitalization, approximately 30% of patients remained clinically congested at discharge. Among clinically euvolemic patients, only 47% showed no evidence of subclinical congestion. Correlations between congestion markers were weak to moderate, suggesting complementary pathophysiological information. At discharge, pulmonary B-lines were the strongest predictor of the composite endpoint (hazard ratio [HR] 3.50, 95% CI 1.41–8.72), followed by clinical congestion (HR 2.67, 95% CI 1.13–6.30). Patients with both clinical and subclinical congestion had the lowest event-free survival, approximately 50% at six months of follow-up (log-rank p = 0.03). Conclusions: Subclinical congestion is common despite apparent clinical euvolemia and is associated with worse outcomes. Integrating clinical assessment with non-invasive congestion markers may improve post-discharge risk stratification and patient management in HF.

20 August 2026 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
DSDavid SánChez-Ortiz
David SánChez-Ortiz
MRMercedes Rivas-Lasarte
Mercedes Rivas-Lasarte
ANAlejandro Nistal-Juarez
Alejandro Nistal-Juarez
LBLuis Blanco-Tapia
Luis Blanco-Tapia
MFMiguel Fribourg
Miguel Fribourg
JCJavier Segovia Cubero
Javier Segovia Cubero
Aims: The use of cardiac signal-recording tools to monitor prognostic and diagnostic parameters in heart failure (HF) is an emerging field, constrained by usability and a low signal-to-noise environment. We evaluated a compact, user-friendly prototype for simultaneous acquisition of phonocardiography, photoplethysmography, electrocardiography, and subsequent processing to determine this strategy’s usefulness in identifying parameters related to HF decompensation. Methods and results: We conducted a single-centre prospective study of 41 hospitalized patients; 36 included in the analysis. Autonomous recordings of phonocardiography, electrocardiography, and pulse-wave photoplethysmography were obtained. Signal processing employed a new supervised iterative filtering pipeline based on detection of coupled energy peaks, together with an independent analysis of the pulse-wave plethysmogram, enabling extraction of clinically relevant intervals even when one modality was of insufficient quality. In the cohort admitted with decompensated HF, measures at discharge showed shortening of electromechanical coupling time (0.148 ± 0.051 vs. 0.108 ± 0.039 s; P < 0.001), isovolumetric contraction time (0.152 ± 0.098 vs. 0.071 ± 0.023 s; P < 0.001), and ejection period (0.257 ± 0.078 vs. 0.344 ± 0.082 s; P < 0.0001) compared with admission. These findings were corroborated against the cardiology inpatient cohort without clinical congestion and contextualized using a publicly available cohort of 338 healthy individuals. Conclusion: This study presents initial evidence that a compact, easy-to-use device permits autonomous acquisition of diagnostic cardiac signals by non-expert users and that the proposed processing strategy reliably detects clinically relevant intervals in low-signal-to-noise ratio recordings, supporting its potential utility for monitoring patients with HF.